LKLenka Krskova

Lenka Krskova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lenka Krskova has a total of 562 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcriptomic analysis reveals distinct expression patterns in focal cortical dysplasia

    by Shivani Sonawane, Michal Hendrych, Michaela Ručková, Robin Jugas, Jan Vrbský, Martin Pail, Barbora Straka, Martina Strnadová, Lenka Krsková, Adam Vácha, et al.

    Objective: Focal cortical dysplasia (FCD) is a common cause of drug‐resistant epilepsy in children and adults and exhibits substantial clinical and histopathological heterogeneity. However, morphological classification alone does not fully explain variability in epileptogenicity, disease severity, or treatment response. Methods: We aimed to define molecular mechanisms underlying FCD heterogeneity using integrated transcriptomic and regulatory analyses. RNA and small RNA sequencing (RNA‐seq) were conducted on cortical tissue resected during epilepsy surgery from 66 patients with histopathologically confirmed FCD subtypes IA ( n = 17), IIA ( n = 25), and IIB ( n = 24), along with 15 postmortem cortical control samples. Differential expression and weighted gene coexpression network analysis were used to identify coordinated transcriptional programs, and microRNA (miRNA) profiling was integrated to assess posttranscriptional regulatory mechanisms. Integrative multivariate analyses (DIABLO and sparse partial least squares discriminant analysis) were used to evaluate subtype discrimination, and findings were validated using an independent RNA‐seq dataset. Results: FCD subtypes showed distinct but partially overlapping molecular profiles. FCD IA showed a comparatively subtle transcriptional profile, dominated by reduced expression of genes involved in cortical development, neuronal signaling, ion regulation, and metabolic stress. FCD IIA displayed a modest yet coherent molecular signature involving developmental and neuronal disruption, together with metabolic stress and autophagy. FCD IIB exhibited the most extensive transcriptional remodeling, including activation of antigen presentation pathways, complement activation, cytoskeleton reorganization, synaptic alterations, and extracellular matrix organization. Differential miRNA profiling identified shared miRNAs, including miR‐320 family, miR‐27a‐5p, miR‐142‐5p, and miR‐21‐5p, alongside subtype‐specific regulatory patterns. Integration of messenger RNA and miRNA data revealed concordant alterations, indicating that miRNA dysregulation may contribute to stabilization of subtype‐specific transcriptional states. Significance: These findings demonstrate that FCD is characterized by coordinated transcriptional and posttranscriptional network alterations that extend beyond morphological classification and may contribute to variability in epileptogenicity across subtypes.

  • Electroclinical characteristics, genetic findings, and complex epilepsy surgery outcomes in children with low‐grade epilepsy‐associated tumors: A comprehensive view

    by Gonzalo Alonso Ramos Rivera, Barbora Straka, Petr Jezdík, Alice Maulisová, KateřIna Bukačová, Martin Kudr, Alena Jahodová, Aněžka Bělohlavková, Martin Kynčl, Zuzana Holubová, et al.

    Objective: To evaluate outcomes in relation to epilepsy characteristics and genetic findings in pediatric patients with isolated low‐grade epilepsy‐associated tumors (LEAT) and LEAT plus focal cortical dysplasia type IIIb (FCD IIIb) who underwent epilepsy surgery. Methods: Patients younger than 19 years at the time of surgery, with isolated LEAT or LEAT plus FCD IIIb, and a minimum follow‐up of 2 years were included. Clinical, neuroimaging, EEG, neuropsychological, surgical, histopathological, and molecular‐genetic data were analyzed. Outcomes and potential predictors were assessed across four domains: seizures, antiseizure medication (ASM) use, cognition (Full Scale Intelligence Quotient, FS‐IQ), and postoperative surgical complications. Results: Seventy‐one children fulfilled the inclusion criteria. Fifty‐one (71.8%) had drug‐resistant epilepsy. LEAT plus FCD IIIb were more frequent (43/71, 60.6%) than isolated LEAT (28/71, 39.4%). Gangliogliomas were the most common tumor type (39/71, 54.9%), followed by dysembryoplastic neuroepithelial tumors (16/71, 22.5%). Genetic testing demonstrated internal tandem duplication of the FGFR1 gene in most isolated LEAT cases (OR 11.9, 95% CI 1.32–100, p = .02), while LEAT+FCD IIIb cases were more frequently negative (OR 3.8, 95% CI 1.3–10.9, p = .02). After a median 5.7‐year follow‐up, 64 patients (90.1%) were seizure‐free, and 55 (77.5%) discontinued ASM. Earlier seizure onset, longer epilepsy duration, and a higher number of ASM correlated with lower pre‐ and postoperative FS‐IQ. A postoperative FS‐IQ gain of >15 points occurred in four patients (7.7%). Two patients (2.8%) had unexpected permanent deficits, and 10 (14.1%) had minor temporary deficits. Significance: Epilepsy surgery leads to high rates of freedom from seizures and ASM in pediatric patients with LEAT and LEAT + FCD IIIb. Early surgical intervention can be associated with higher pre‐ and postoperative FS‐IQ. Molecular‐genetic findings suggest distinct neoplastic and dysplastic entities of LEAT and LEAT plus FCD IIIb.

  • Open Access

    Clinicopathological features of CIC-rearranged sarcomas: a retrospective study including novel visceral locations and methylation profile analysis

    by Jan Balko, Filip Kukla, Lenka Krskova, Lucie Stolová, Ales Vicha, Josef Zamecnik

    CIC-rearranged sarcomas represent a distinct rare pathological entity within the spectrum of undifferentiated small round cell sarcomas. This single institution retrospective study investigates the histopathological, molecular, and clinical characteristics of a cohort of 14 CIC-rearranged sarcomas. These tumors were diagnosed in eight male and six female patients, with the age at initial diagnosis ranging from 8 to 67 years and a mean age of 23.7 years. Among the patients, three novel locations of CIC::DUX4 sarcomas were detected in the mesentery, pancreas, and pterygopalatine fossa. Genetically, we identified 12 cases as CIC::DUX4 sarcomas and two as sarcomas with CIC gene rearrangement detected by break-apart fluorescence in situ hybridization only. The most common gene translocation had a breakpoint located in exon 20 of the CIC gene and exon 1 of the DUX4 gene; this alteration was found in 83% of all CIC::DUX4 cases we identified. We also performed DNA methylation analysis on seven cases, which was proven to be a reliable method with high sensitivity for clustering CIC-rearranged sarcomas.


  • Open Access

    Molecular Landscape of Pediatric Low‐Grade Gliomas: Insights From RNA ‐ NGS and Bioinformatic Analysis

    by Petr Brož, Martina Strnadová, Denisa Olejníková, Johana Kotiš, Tereza Pospíšilíková, Adéla Mišove, Miroslav Koblížek, Josef Zámečník, Michal Zápotocký, David Sumerauer, et al.

    Pediatric low‐grade gliomas (pLGG) are the most common group of childhood brain tumors. Genetic alterations in the RAS–RAF–mitogen‐activated protein kinase (MAPK) pathway are the molecular drivers in the vast majority of pLGG. A large proportion of pediatric pLGG are characterized by the presence of fusion genes. An institutional molecular analysis together with an RNA‐NGS study was performed to reveal LGG‐associated molecular alterations. In our cohort of pLGG patients, molecular alterations were identified in 318 out of 342 cases (92.9%) through a combination of RT‐PCR, Sanger sequencing, and NGS methodologies. Fusion events were independently called using three fusion callers: Archer Analysis 6.0 and/or 7.0, Arriba version 2.4, and STAR‐Fusion 24. Among these, STAR‐Fusion had the lowest sensitivity, detecting rearrangements in only 67% of fusion‐positive cases. In contrast, Arriba detected rearrangements in 97.77% of cases, while Archer detected rearrangements in 88.6% of cases. These findings highlight differences in detection efficiency among fusion callers, emphasizing the importance of tool selection in molecular diagnostics. The detection of fusion genes is very important for correct diagnosis, prognosis, and adequate targeted treatment.


  • Open Access

    A case series of newly described rare mesenchymal tumors of the knee and the role of molecular testing in their histopathological diagnosis

    by Jan Balko, William Golas, Petr Skapa, Jaromir Hacek, Lenka Krskova, Marcela Mrhalova, Josef Zamecnik

  • Open Access

    NTRK1-rearranged histiocytosis: clinicopathologic and molecular features

    by Rivers Fragneau, Sylvie Fraitag, Paul G. Kemps, Zofia Hélias-Rodzewicz, Somak Roy, Benjamin Bonsang, Allison L. Bartlett, Subhra Dhar, Martin Jankofsky, Jozef Zlocha, et al.

    Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. Through international collaboration, we investigated 50 cases of histiocytosis with pan-tropomyosin receptor kinase (pan-TRK) expression and/or in-frame NTRK rearrangement. We also analyzed 45 control xanthogranulomas using pan-TRK immunohistochemistry and targeted RNA sequencing. Slides were centrally reviewed; clinical and molecular data were collected. The 50 cases comprised 30 children and 20 adults with a median age of 11.5 years (range, 0-73 years) and a male predominance (64%). Most patients (88%) had disease limited to the skin, including a single skin nodule in 41 patients and multiple skin lesions in 3 others. Four newborns presented with skin lesions, hepatomegaly, and thrombocytopenia that required transfusions. The 2 remaining patients had life-threatening lesions of the brain or bronchus. All cases displayed xanthogranuloma histology, often including foamy histiocytes and Touton giant cells. Histiocytes stained positive for pan-TRK in 50 of 50 cases, whereas all 45 control xanthogranulomas without in-frame NTRK fusions stained negative. NTRK1 fusion partners included IRF2BP2 (23/46), TPM3 (12/46), SQSTM1 (3/46), PRDX1 (3/46), NPM1 (2/46), LMNA (2/46), and ARHGEF2 (1/46). Clinical outcomes were favorable, including spontaneous disease regression in 3 of 4 newborns with systemic disease, and rapid clinical response in both patients with a brain or bronchial tumor treated with the TRK inhibitor larotrectinib. This study advances the molecular characterization of histiocytoses and may guide the diagnosis and personalized treatment of patients.


  • Open Access

    Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

    by Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, et al.

    Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma

  • Open Access

    Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

    by Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, et al.

    Supplementary Table S4. Other molecular alterations reported.

  • Open Access

    Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

    by Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, et al.

    Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.

  • Open Access

    Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

    by Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, et al.

    Supplementary Table S1. NTRK fusion type and histology.